ReviewLung Cancer (Auckland, N.Z.)2018
Comprehensive review of fetal adenocarcinoma of the lung.
Review in Lung Cancer (Auckland, N.Z.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- Moving Through Genetic Alterations and PD-L1 Expression in High-Grade Fetal Adenocarcinoma of the Lung: A Case Report and Literature Review.International medical case reports journal · 2025Article
- Prominent response to savolitinib monotherapy in high-grade fetal adenocarcinoma withTranslational lung cancer research · 2024Article
- Molecular landscape and multi-omic measurements of heterogeneity in fetal adenocarcinoma of the lung.NPJ precision oncology · 2024Article
- [High-grade Fetal Adenocarcinoma of the Lung with Scalp Metastasis: A Case Report].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Article
- Uniportal video-assisted thoracoscopic segmentectomy for fetal adenocarcinoma lung cancer with severe pulmonary emphysema: a case report.Frontiers in oncology · 2024Article
- A case report of high-grade fetal lung adenocarcinoma with KRAS mutation.Respiratory medicine case reports · 2024Article
- Successful treatment with atezolizumab combination chemotherapy in a patient with high-grade fetal adenocarcinoma of the lung: A case report.Thoracic cancer · 2023Article
- High-grade fetal adenocarcinoma of the lung misdiagnosed as male breast carcinoma: a case report and literature review.Frontiers in oncology · 2023Article
- Article
- Distinct properties of pure- and mixed-type high-grade fetal lung adenocarcinomas by genetic profiling and transcription factor expression.Virchows Archiv : an international journal of pathology · 2022Article
- Both the serum AFP test and AFP/GPC3/SALL4 immunohistochemistry are beneficial for predicting the prognosis of gastric adenocarcinoma.BMC gastroenterology · 2021Article
- Novel genetic characteristics in low-grade fetal adenocarcinoma of the lung.Thoracic cancer · 2021Article
- High-grade fetal adenocarcinoma of the lung with abnormal expression of alpha-fetoprotein in a female patient: Case report.Medicine · 2021Article
- Combined large cell neuroendocrine carcinoma of the lung associated with low-grade fetal adenocarcinoma withoutInternational journal of clinical and experimental pathology · 2021Article
- Coexistence of Low-Grade Fetal Adenocarcinoma and Adenocarcinoma in situ of the Lung Harboring Different Genetic Mutations: A Case Report and Review of Literature.OncoTargets and therapy · 2020Article
- Co-existence of well-differentiated fetal adenocarcinoma of the lung with tuberculosis in a young female: A rare case report.Medicine · 2019Article
- [18F]FDG- PET/CT in Staging and Restaging of Fetal Type Adenocarcinoma of the Lung: A Case Report and a Review of the Literature.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fetal adenocarcinoma of the lung (FLAC) is a rare tumor. It accounts for ~0.1%-0.5% of all pulmonary neoplasms. Due to its rarity, much of the world literature regarding FLAC comes from case reports and case series. FLAC is an adenocarcinoma resembling developing fetal lung in its pseudoglandular stage (8-16 weeks of gestation). It is distinguishable from pulmonary blastoma (PB) because it lacks the mesenchymal component which is a hallmark finding in PB. Due to differences in histopathology and clinical course, FLAC has been further categorized into low-grade (L-FLAC) and high-grade (H-FLAC) forms. L-FLAC displays low nuclear atypia and prominent morule formation and has a pure pattern. H-FLAC typically presents with at least 50% fetal morphology, and is often associated with other conventional types of lung adenocarcinoma. FLAC expresses neuroendocrine markers and thyroid transcription factor 1 in most cases. L-FLAC has an aberrant nuclear/cytoplasmic expression of β-catenin and presents mutations in this gene. H-FLAC overexpresses p53. These tumors have a very low frequency of mutations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.